BEERS REMS
OTC
Absorption: 90% absorbed following oral administration; food ↓ absorption.
Distribution: Unknown.
Protein Binding: 97%.
Half-Life: Children 111 yr: 0.420.88 hr; Adults: 1.01.5 hr.
(plasma concentrations*)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | rapid | 1.6 hr | 24 hr |
IV | rapid | end of infusion | 24 hr |
*Resolution of symptoms takes 58 days.
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, cutaneous lupus erythematosus, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
F and E: hypocalcemia (especially if treatment duration ≥3 mo), hypokalemia (especially if treatment duration ≥3 mo), hypomagnesemia (especially if treatment duration ≥3 mo)
GI: abdominal pain, CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD), constipation, diarrhea, dry mouth, flatulence, fundic gland polyps, nausea
GU: acute tubulointerstitial nephritis
Hemat: vitamin B12 deficiency
MS: bone fracture
Neuro: headache
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS, ANGIOEDEMA, OR TUBULOINTERSTITIAL NEPHRITIS), systemic lupus erythematosus
Drug-drug:
Drug-Natural Products:
Gastroesophageal Reflux Disease
Hepatic Impairment
Reduction of Risk of Rebleeding of Gastric or Duodenal Ulcers After Therapeutic Endoscopy
Hepatic Impairment
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence (Triple Therapy)
Hepatic Impairment
Reduction in Risk of Gastric Ulcer During Continuous NSAID Therapy
Hepatic Impairment
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
Hepatic Impairment
Lab Test Considerations:
Do not confuse Nexium with Nexavar.
IV Administration:
H. pylori
in duodenal ulcer disease.NDC Code